These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38940925)

  • 21. Belimumab for systemic lupus erythematosus.
    Singh JA; Shah NP; Mudano AS
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.
    Margiotta DPE; Basta F; Batani V; Afeltra A
    BMC Nephrol; 2018 Mar; 19(1):54. PubMed ID: 29514612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study.
    Yamane T; Hashiramoto A
    Lupus; 2024 May; 33(6):598-607. PubMed ID: 38509864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.
    Fließer EE; Korsten P; Koziolek MJ; Niewold TB; Patschan D; Müller GA; Patschan SA
    Lupus; 2013 Dec; 22(14):1523-5. PubMed ID: 24014569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review.
    Zhang C; Zeng M; Ge Y; Liu K; Xing C; Mao H
    Front Immunol; 2022; 13():977377. PubMed ID: 36172377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.
    Gheet FS; Dawoud HE; El-Shahaby WA; Elrifaey SM; Abdelnabi HH
    Eur J Pediatr; 2023 Apr; 182(4):1685-1695. PubMed ID: 36752895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
    Atisha-Fregoso Y; Malkiel S; Harris KM; Byron M; Ding L; Kanaparthi S; Barry WT; Gao W; Ryker K; Tosta P; Askanase AD; Boackle SA; Chatham WW; Kamen DL; Karp DR; Kirou KA; Sam Lim S; Marder B; McMahon M; Parikh SV; Pendergraft WF; Podoll AS; Saxena A; Wofsy D; Diamond B; Smilek DE; Aranow C; Dall'Era M
    Arthritis Rheumatol; 2021 Jan; 73(1):121-131. PubMed ID: 32755035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful management of belimumab after obinutuzumab in a patient with systemic lupus erythematosus: a case report with an 18-month follow-up.
    Pu X; Ye Q; Zhu L; Yan T
    Front Immunol; 2024; 15():1459241. PubMed ID: 39421753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study.
    Wang D; Shan C; Liu J; Zhang R; Zhu G; Gao T; Chang H; Gao S; Bai C; Nie N; Zhang Q; Lin Y
    Front Immunol; 2022; 13():1067721. PubMed ID: 36591249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis.
    Zhao L; Wang W; Wu L; Wu T; Tu J; Wu X; Sun F; Ding H; Shen N; Wu H; Zhu J; Sun L; Ye S
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38806217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppressive treatment for proliferative lupus nephritis.
    Tunnicliffe DJ; Palmer SC; Henderson L; Masson P; Craig JC; Tong A; Singh-Grewal D; Flanc RS; Roberts MA; Webster AC; Strippoli GF
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD002922. PubMed ID: 29957821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
    Deng WP
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
    Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
    Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
    Zhang M; Qi C; Zha Y; Chen J; Luo P; Wang L; Sun Z; Wan J; Xing C; Wang S; Jiang G; Sun M; Chen Q; Chen J; Li D; Guan T; Ni Z
    Clin Rheumatol; 2019 Mar; 38(3):859-867. PubMed ID: 30426311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
    Fan Q; Yang H; Liu Y
    Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
    Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
    Sada K; Kurita N; Noma H; Matsuki T; Quasny H; Levy RA; Jones-Leone AR; Gairy K; Yajima N
    Lupus Sci Med; 2022 Sep; 9(1):. PubMed ID: 37017254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
    Aragon E; Resontoc LP; Chan YH; Lau YW; Tan PH; Loh HL; Ng KH; Yap HK
    Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.